Literature DB >> 8393685

Effects of lisinopril on cardiorespiratory, neuroendocrine, and renal function in patients with asymptomatic left ventricular dysfunction.

J G Cleland1, D Shah, S Krikler, A Dritsas, P Nihoyannopoulos, G Frost, C M Oakley.   

Abstract

OBJECTIVE: To determine the cardiac, renal, and neuroendocrine effects of lisinopril in men with untreated, symptom free left ventricular systolic dysfunction.
DESIGN: A randomised, double blind cross over trial with six week treatment periods to compare lisinopril (10 mg/day) and matching placebo.
SETTING: Hospital outpatient department. PATIENTS: Patients with pronounced systolic dysfunction on cross sectional echocardiography due to myocardial infarction at least six months previously, without angina and with no or minimal breathlessness. Eighteen men were identified of whom 15 completed the study.
INTERVENTIONS: Lisinopril (10 mg) or placebo given once daily by mouth. MAIN OUTCOME MEASURES: Primary: oxygen consumption at peak exercise. Secondary: resting cardiac function as measured by radionuclide ventriculography and echocardiography, renal function estimated radioisotopically, and plasma indices of neuroendocrine activity.
RESULTS: Compared with placebo, lisinopril increased (mean (SD)) peak oxygen consumption during exercise (19.8(3.1) ml/kg/min v 21.4(3.2) ml/kg/min; p < 0.003). Lisinopril did not improve indices of cardiac function at rest. It reduced plasma concentrations of angiotensin II (median values 7 pg/ml to 5 pg/ml; p < 0.02), aldosterone (median values 113 pg/ml to 66 pg/ml; p < 0.05) and atrial natriuretic peptide (median values 69 pg/ml to 40 pg/ml; p < 0.04), but noradrenaline and antidiuretic hormone concentrations did not change. Renal blood flow increased and glomerular filtration rate declined.
CONCLUSIONS: Even before the onset of heart failure lisinopril improves the cardiopulmonary response to exercise in patients with systolic ventricular dysfunction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8393685      PMCID: PMC1025162          DOI: 10.1136/hrt.69.6.512

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  15 in total

1.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Authors:  J N Cohn; G Johnson; S Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

2.  Measurement of plasma angiotensin II.

Authors:  J J Morton; D J Webb
Journal:  Clin Sci (Lond)       Date:  1985-04       Impact factor: 6.124

3.  Noninvasive measurement of blood flow and extraction fraction.

Authors:  A M Peters; R D Gunasekera; B L Henderson; J Brown; J P Lavender; M De Souza; J M Ash; D L Gilday
Journal:  Nucl Med Commun       Date:  1987-10       Impact factor: 1.690

4.  Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group.

Authors:  T D Giles; R Katz; J M Sullivan; P Wolfson; M Haugland; P Kirlin; E Powers; S Rich; B Hackshaw; A Chiaramida
Journal:  J Am Coll Cardiol       Date:  1989-05       Impact factor: 24.094

5.  Angiotensin II-forming pathways in normal and failing human hearts.

Authors:  H Urata; B Healy; R W Stewart; F M Bumpus; A Husain
Journal:  Circ Res       Date:  1990-04       Impact factor: 17.367

6.  Neuroendocrine activation after acute myocardial infarction.

Authors:  H M McAlpine; J J Morton; B Leckie; A Rumley; G Gillen; H J Dargie
Journal:  Br Heart J       Date:  1988-08

7.  The renin-angiotensin-aldosterone system in congestive failure in conscious dogs.

Authors:  L Watkins; J A Burton; E Haber; J R Cant; F W Smith; A C Barger
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

8.  Factors determining symptoms in heart failure: comparison of fast and slow exercise tests.

Authors:  D P Lipkin; R Canepa-Anson; M R Stephens; P A Poole-Wilson
Journal:  Br Heart J       Date:  1986-05

9.  Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.

Authors:  J G Cleland; H J Dargie; S G Ball; G Gillen; G P Hodsman; J J Morton; B W East; I Robertson; I Ford; J I Robertson
Journal:  Br Heart J       Date:  1985-09

10.  Plasma alpha natriuretic peptide in cardiac impairment.

Authors:  A M Richards; J G Cleland; G Tonolo; G D McIntyre; B J Leckie; H J Dargie; S G Ball; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-16
View more
  8 in total

Review 1.  Lisinopril: a review of its use in congestive heart failure.

Authors:  K Simpson; B Jarvis
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

2.  Fluid Management in Patients with Chronic Heart Failure.

Authors:  Pierpaolo Pellicori; Kuldeep Kaur; Andrew L Clark
Journal:  Card Fail Rev       Date:  2015-10

Review 3.  Lisinopril. A review of its pharmacology and clinical efficacy in the early management of acute myocardial infarction.

Authors:  K L Goa; J A Balfour; G Zuanetti
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 4.  ACE inhibitors for heart failure: a question of dose.

Authors:  J G Cleland; P A Poole-Wilson
Journal:  Br Heart J       Date:  1994-09

Review 5.  How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death?

Authors:  J G Cleland; S Puri
Journal:  Br Heart J       Date:  1994-09

Review 6.  Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients.

Authors:  H D Langtry; A Markham
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 7.  Renin-angiotensin-aldosterone inhibition improves right ventricular function: a meta-analysis.

Authors:  Jacob Y Cao; Seung Yeon Lee; Kevin Phan; David S Celermajer; Sean Lal
Journal:  Heart Asia       Date:  2018-05-03

8.  Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction : meta-analysis of randomised clinical trials.

Authors:  Antònia Agustí; Sara Bonet; Josep Maria Arnau; Xavier Vidal; Joan-Ramon Laporte
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.